Transdur-Bupivacaine is a transdermal pain patch in Phase II trials.

Durect entered into a long-term manufacturing and supply deal with Corium International for Durect’s Phase II post-shingles pain treatment. Transdur™-Bupivacaine is a transdermal pain patch.

“Corium’s flexible capabilities, expertise, and collaborative capacity in manufacturing transdermal products makes them an ideal partner for us,” remarks James Brown, CEO of Durect.

According to the agreement, Corium will provide Durect’s clinical and commercial supplies of Transdur-Bupivacaine on a worldwide basis.

Transdur-Bupivacaine is intended to provide up to three days of pain relief for patients suffering from post-shingles pain, as compared to a wearing time limited to 12 hours with currently available patches. Durect has begun its Phase II program with a randomized, multicenter, double-blind, placebo-controlled, two-way crossover trial in approximately 50 patients with post-herpetic neuralgia, also known as post-shingles pain, to assess safety as well as the magnitude, duration, and characteristics of analgesic activity of Transdur-Bupivacaine.

Previous articleAnacor Could Make $625M in Deal with Schering-Plough
Next articleMaas Biolab Joins Efforts to Develop Brain-Protecting Drug Against Nerve Agents